Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 17/20 | 0.46 |
| ▸ | SCN1A | P35498 | 12/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537609 | 0.93 | HCRTR1 (0.46) | SCN8ASCN1AHRH3CYP2D6HCRTR1 | |
| SCHEMBL5532351 | 0.88 | HCRTR1 (0.44) | SCN8ASCN1ACYP2D6HCRTR1HCRTR2 | |
| SCHEMBL5528217 | 0.83 | HRH3 (0.52) | HRH3CYP2D6HCRTR1HCRTR2 | |
| SCHEMBL5532322 | 0.81 | SLC2A1 (0.45) | HRH3HCRTR1HCRTR2 | |
| SCHEMBL5531767 | 0.79 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL5526609 | 0.78 | SCN8A (0.49) | SCN8ASCN1A | |
| SCHEMBL5532963 | 0.78 | NCF1 (0.58) | HRH3 | |
| SCHEMBL5532160 | 0.78 | HTR1D (0.44) | HRH3HCRTR1HCRTR2 | |
| SCHEMBL5528119 | 0.77 | ADAM17 (0.44) | HRH3HCRTR1HCRTR2 | |
| SCHEMBL5537598 | 0.76 | NCF1 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | SCN8A 117/4885SCN1A 105/4885HRH3 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.